Astellas/Pfizer’s Xtandi Given FDA’s Priority Review for Hormone-Sensitive Prostate Cancer

Astellas Pharma and its partner Pfizer said on August 21 that the US FDA has granted a priority review status for Xtandi (enzalutamide) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), with the agency’s decision expected by...read more